A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases
Jung-Yoon ChoeJ Smolen

Abstract

To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. This is a phase III, randomised, double-blind, multinational, multicentre parallel group study. Patients with moderate to severe RA despite methotrexate therapy were randomised in a 1:1 ratio to receive either SB2 or INF of 3 mg/kg. The primary end point was the American College of Rheumatology 20% (ACR20) response at week 30. Inclusion of the 95% CI of the ACR20 response difference within a ±15% margin was required for equivalence. 584 subjects were randomised into SB2 (N=291; 290 analysed) or INF (N=293). The ACR20 response at week 30 in the per-protocol set was 64.1% in SB2 versus 66.0% in INF. The adjusted rate difference was -1.88% (95% CI -10.26% to 6.51%), which was within the predefined equivalence margin. Other efficacy outcomes such as ACR50/70, disease activity score measured by 28 joints and European League against Rheumatism response were similar between SB2 and INF. The incidence of treatment-emergent adverse events was comparable (57.6% in SB2 vs 58.0% in INF) as well as the incidence of antidrug antib...Continue Reading

References

Feb 8, 2006·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·W F LemsB A C Dijkmans
Apr 28, 2006·Statistics in Medicine·UNKNOWN Committee for Medicinal Products for Human UseUNKNOWN Committee for Release for Consultation
Apr 28, 2006·Statistics in Medicine·UNKNOWN Committee for Medicinal Products for Human UseUNKNOWN Committee for Release for Consultation
Nov 17, 2009·Current Medical Research and Opinion·Howard BirnbaumMary Cifaldi
Sep 21, 2011·Pharmaceutical Statistics·Bernhard HuitfeldtUNKNOWN European Federation of Statisticians in the Pharmaceutical Industry (EFSPI)
Dec 21, 2012·Annals of the Rheumatic Diseases·Thomas DörnerGerd R Burmester
Jul 31, 2013·Annals of the Rheumatic Diseases·Jonathan Kay, Josef S Smolen
Feb 20, 2014·Annals of the Rheumatic Diseases·Marita CrossLyn March
May 17, 2014·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Valentin BrodszkyMárta Péntek
Sep 28, 2014·Blood Reviews·Bradford R Hirsch, Gary H Lyman
Dec 18, 2014·MAbs·Soon Kwan JungShin Jae Chang
May 20, 2015·Clinical and Molecular Allergy : CMA·Carlo AgostiniEnrico Maggi
Nov 1, 2013·Therapeutic Innovation & Regulatory Science·Russell ReeveWei Xiao

❮ Previous
Next ❯

Citations

May 18, 2016·Journal of Immunology Research·Roy Jefferis
Nov 4, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ira JacobsSadiq Lula
Aug 28, 2016·Annals of the Rheumatic Diseases·Jonathan Kay, John D Isaacs
Jan 11, 2017·Expert Opinion on Drug Safety·J Braun, J Kay
Mar 28, 2017·Postgraduate Medicine·Daniel M GeynismanIra Jacobs
Mar 18, 2017·Current Opinion in Rheumatology·Stanley Cohen, Jonathan Kay
May 31, 2017·The British Journal of Dermatology·N GonzalezG Han
Apr 25, 2018·Expert Opinion on Biological Therapy·Zsuzsanna KurtiPeter L Lakatos
Apr 24, 2018·Expert Opinion on Biological Therapy·Alexis JonesPedro M Machado
Oct 27, 2017·Immunotherapy·Salvatore BellinviaChristopher Edwards
Nov 10, 2018·Alimentary Pharmacology & Therapeutics·Brian G FeaganGary R Lichtenstein
Dec 24, 2018·Expert Opinion on Biological Therapy·Mercedes Gimeno-GraciaFernando Gomollón
Oct 20, 2018·International Journal of Rheumatic Diseases·Prasan Deep RathLyndon Llamado
Sep 1, 2018·Journal of Pediatric Gastroenterology and Nutrition·Lissy de RidderUNKNOWN Paediatric IBD Porto group of ESPGHAN
Feb 1, 2018·Zeitschrift für Rheumatologie·J BraunT Dörner
Jul 31, 2018·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Valderilio Feijó AzevedoHeather E Jones
Mar 2, 2018·Current Treatment Options in Gastroenterology·Frank I Scott, Gary R Lichtenstein
Nov 4, 2016·Nature Reviews. Gastroenterology & Hepatology·Silvio DaneseLaurent Peyrin-Biroulet
May 23, 2019·Alimentary Pharmacology & Therapeutics·Antoine MeyerAlain Weill
Jul 20, 2019·Expert Review of Gastroenterology & Hepatology·Laurent Peyrin-BirouletTaegyun Kang
Oct 17, 2019·Cadernos de saúde pública·Paula Teixeira Pinto Ferreira NetoMarco Antonio Vargas
Mar 3, 2020·Expert Opinion on Drug Safety·Kelly A ReynoldsJashin J Wu
Sep 4, 2017·Annals of the Rheumatic Diseases·Jonathan KayUNKNOWN Task Force on the Use of Biosimilars to Treat Rheumatological Diseases
Feb 21, 2018·Current Opinion in Rheumatology·Tina D Mahajan, Ted R Mikuls
Aug 24, 2018·Inflammatory Bowel Diseases·Alessandro ArmuzziUNKNOWN PROSIT Investigators
Feb 7, 2017·Current Treatment Options in Gastroenterology·Shannon Chang, Stephen Hanauer
Sep 15, 2017·Rheumatology·Hendrik Schulze-Koops, Alla Skapenko
Feb 9, 2018·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Sascha GerdesMarc A Radtke
Aug 28, 2018·World Journal of Clinical Cases·Flyn Kaida-YipDinesh Vyas
Oct 27, 2018·Current Clinical Pharmacology·Efraín EstebanEdwin Jáuregui
Feb 7, 2019·International Journal of Technology Assessment in Health Care·Emma L SimpsonSalah Ghabri
Oct 19, 2019·Expert Review of Clinical Immunology·Fabrizio CantiniLaura Niccoli

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
ELISA

Clinical Trials Mentioned

NCT01936181

Software Mentioned

R
WinNonlin
SAS
Cenduit
PLANETRA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.